Trial Profile
Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics
- 21 Mar 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.
- 21 Sep 2020 Planned number of patients changed from 15 to 30.
- 08 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2022.